−0.159SEK
−54.08 MSEK
78.00 KSEK
318.48 M
About XINTELA AB
Sector
Industry
CEO
Evy Lundgren-Åkerlund
Website
Headquarters
Lund
Founded
2009
ISIN
SE0007756903
FIGI
BBG00CGSPCY3
Xintela AB engages in the development of pharmaceutical products. Its technology include XINMARK, which provides a means to detect certain tumour cells and to target treatment to the cells in order to slow tumour growth. The firm is also in the process of development of XACT, used in the quality assurance of methods and cells in the company’s own development activities for stem cell products. The company was founded by Evy Lundgren-Akerlund and Rickard Mosell in 2009 and is headquartered in Lund, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of XINT is 0.275 SEK — it has decreased by 2.14% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange XINTELA AB stocks are traded under the ticker XINT.
XINTELA AB is going to release the next earnings report on May 24, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track XINTELA AB financials in yearly and quarterly reports right on TradingView.
Like other stocks, XINT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XINTELA AB stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XINTELA AB EBITDA is −55.19 M SEK, and current EBITDA margin is −70.75 K%. See more stats in XINTELA AB financial statements.